###### Strengths and limitations of this study

-   Ours is the first study to characterise β-thalassaemia in the Yunnan province, which may be useful to improve screening and prenatal diagnosis in Southwestern China.

-   Our study determined that a higher cut-off point of haemoglobin alpha 2 levels (HbA~2~ ≥4.0%) should be used for β-thalassaemia screening, rather than the current value of 3.5%.

-   Samples for participants used for capillary electrophoresis, cut-off value calculation and characterisation of β-thalassaemia were not collected at the same time.

Introduction {#s1}
============

β-Thalassaemia is an inherited anaemia resulting from genome variants in β-globin chains. This disease is most prevalent in Africa,[@R1] Asia,[@R2] Mediterranean[@R3] and the Middle East.[@R4] Quantification of haemoglobin alpha 2 (HbA~2~) percentage by capillary electrophoresis and routine haematology testing are the existing methods for screening thalassaemia and haemoglobinopathies.[@R5] An HbA~2~ value exceeding 3.5% combined with a low mean cell volume (MCV) and mean cell haemoglobin (MCH) are the current diagnostic criteria for β-thalassaemia carriers. Determination of the haemoglobin (Hb) concentration and HbA~2~ range in a population offers a critical screening tool for thalassaemia.[@R6] [@R7] However, there are very few reports on the clinical reference intervals for β-thalassaemia patients in China. Therefore, it is important to determine appropriate diagnostic cut-off points and supplement the existing references to improve the screening and control of β-thalassaemia.

More than 800 different β-globin gene mutations have been discovered worldwide. Two subtypes are defined by totally absent (β^0^) or partially reduced (β^+^) production of normal β chains, respectively. The severity of β-thalassaemia varies with the thalassaemia mutation, ranging from asymptomatic anaemia to a severe transfusion-dependent disorder. Populations in different regions have diversified β-globin gene mutations[@R8] and the ability to identify and characterise these β-thalassaemia mutations can assist in genetic counselling and prenatal diagnoses.[@R9] In this study, we established an HbA~2~ data set for screening β-thalassaemia in people of Southwestern China, and correlated these data to haematological and biochemical values to better understand thalassaemia and to improve its control and prevention.

Materials and methods {#s2}
=====================

Study design {#s2a}
------------

In this study, we performed a retrospective analysis using capillary electrophoresis to determine the HbA~2~ data set, calculated the diagnostic criteria for β-thalassaemia and analysed haematological parameters to provide an additional characterisation of this disease. There were three independent studies conducted during different time periods. The study design is shown in [figure 1](#BMJOPEN2016013367F1){ref-type="fig"}.

![Flow diagram and participant numbers in this study. Capillary electrophoresis, cut-off value calculation, haematological and electrophoretic characterisation of β-thalassaemia mutation were three independent studies conducted during different time periods.](bmjopen2016013367f01){#BMJOPEN2016013367F1}

Setting {#s2b}
-------

This study was conducted in The First Peoples\' Hospital of Yunnan Province. This hospital is located in the Jinbi road of Kunming city. It is a general hospital whose annual clinic amount exceeds 1.6 million people with 2000 beds.

Participants {#s2c}
------------

Participants for three independent studies were collected during three different time periods: (1) a total of 15 067 subjects (3678 men and 11 389 women, 18--45 years of age) who sought thalassaemia screening during September 2011 to July 2014 and had capillary electrophoresis performed; (2) individuals (n=723) with suspected β-thalassaemia (HbA~2~≥3.5%) or abnormal haemoglobin variants were randomly selected from October 2010 to April 2014 (210 men and 513 women, 18--45 years of age) for cut-off value calculation; (3) unrelated heterozygous β-thalassaemia patients (n=486: 151 men and 335 women, 19--58 years of age), were included in the study to analyse haematological and biochemical parameters between June 2009 to April 2013. Written and informed consent were obtained from the patients. The exclusion criteria were: (1) incomplete information, (2) consanguinity, (3) lack of informed consent and (4) children (below the age of 18 years).

Capillary electrophoresis {#s2d}
-------------------------

Venous blood samples were collected from subjects (n=15 067) in tubes containing EDTA. Haemoglobin analysis was performed using capillary electrophoresis (Sebia, Paris, France). Internal quality control was performed by analysing the control materials provided by the manufacturer. Mean comparisons were made among HbA~2~ and HbA by gender, comparing men versus women in each of three age groups: 18--45, 20--29 and 30--39 years using t-test.

DNA extraction and detection of β-globin mutations {#s2e}
--------------------------------------------------

DNA was extracted from whole blood using the blood DNA extraction system (Tianlong Bioscience Shenzhen, Xian, China). Detection of 17 known β-globin gene mutations (97.3% of known β-thalassaemia alleles in Chinese populations) for 723 individuals with suspected β-thalassaemia or abnormal haemoglobin variants were performed by polymerase chain reaction (PCR)-reverse dot-blot method as previously described.[@R10] These 17 β-globin mutations are as follows: CD 41-42 (--TCTT), intervening sequence (IVS)-II-654 (C\>T), −28 (A\>G), CD 71/72 (+A), CD 17 (A\>T), HbE (CD 26, G\>A), CD 31 (--C), CD 27/28 (+C), CD 43 (G\>T), -32 (C\>A), -29 (A\>G), 30 (T\>C), CD 14/15 (+G), Cap+40 to+43 (--AAAC), Initiation CD (T\>G), IVS-I-1 (G\>T) and IVS-I-5 (G\>T). Samples without detected mutations were sequenced on an ABI 3700 automated sequencer using primers that ﬂanked the entire β-globin gene, as previously described.[@R10]

Cut-off value calculation {#s2f}
-------------------------

Sensitivity, specificity, Youden\'s Index (YI), likelihood ratio positive (LRP) and likelihood ratio negative (NRP) of HbA~2~ measurements within the interval of 3.5--4.5% were evaluated. A receiver operating characteristic (ROC) analysis was performed to calculate the area under the curve (AUC). In addition, we calculated the cut-off value with the greatest accuracy to identify β-thalassaemia in our population.

Characterisation of β-thalassaemias {#s2g}
-----------------------------------

Complete blood counts were performed on 486 unrelated β-thalassaemia heterozygous patients that were diagnosed in our centre using an automated cell counter (Sysmex, Tokyo, Japan). Histograms and tables of descriptive statistics of Hb, MCV, MCH, HbA and HbA~2~ were generated and compared by gender (n\>15). Also, HbA, HbA~2~, MCV, MCH and Hb were compared among different genotypes of β-thalassaemia (n\>10). Continuous variables were compared using analysis of variance. For multiple comparisons, a *post hoc* analysis was used when appropriate. Duncan\'s multiple range test was used to decrease type I error rates. All reported p-values are two-sided and were statistically significant if p\<0.05. All statistics in this study were computed with SPSS V.16 for Windows.

Results {#s3}
=======

Subjects screened by capillary electrophoresis {#s3a}
----------------------------------------------

The data distribution of HbA and HbA~2~ measurements performed in the study is shown in online [supplementary figure](#SM1){ref-type="supplementary-material"} S1 and [table](#SM2){ref-type="supplementary-material"} S1. The mean HbA among the subjects was 96.83% (95% CI for mean: 96.81% to 96.84%), while the mean HbA~2~ was 2.91% (95% CI for mean: 2.90% to 2.92%). Out of these subjects, the majority had HbA~2~ levels ranging from 2.4 to 3.5% (95.45%, 14 382/15 067), while 337 cases (2.24%, 337/15 067) had HbA~2~ levels \<2.4% and 348 cases (2.31%, 348/15 067) had HbA~2~ levels \>3.5%. Six subjects lacking an HbA band and five subjects without an HbA~2~ band were identified. The HbF band was present in 4381 subjects (29.08%, 4381/15 067) with a mean percentage of 1.17% (95% CI for mean: 1.02% to 1.33%). There were no significant differences in HbA~2~ levels between male and female in each three age groups (18--45, 20--29 and 30--39) (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1). However, HbA levels were significantly higher in men than in women in all three age groups (18--45, 20--29 and 30--39) (p\<0.01) (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1).
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Cut-off value calculation {#s3b}
-------------------------

Among the total 723 specimens investigated for β-globin gene mutations, 22 different mutations were found in 566 cases (78.28%, 566/723), with HbA~2~ levels ranging from 1.8 to 7.9%. These included a total of 563 β-thalassaemia heterozygotes, one haemoglobin E (HbE) homozygosity and two compound heterozygotes ([table 1](#BMJOPEN2016013367TB1){ref-type="table"}). β-globin mutations were not detected in the remaining 237 subjects. Among β-thalassaemia heterozygotes, HbA~2~ values ranged from 1.8% to 4.0% in 69 of 566 subjects (69/566, 12.19%), while the majority (497/566, 87.81%) had HbA~2~ values ≥4.0%. The sensitivity, speciﬁcity, YI, LRP and NRP of each selected cut-off point in screening for β-thalassaemia are summarised in [table 2](#BMJOPEN2016013367TB2){ref-type="table"}. Regarding haematological parameters, HbA~2~ at the new cut-off value of 4.0% yielded high values (0.898, 95% CI 0.874 to 0.919) for AUC and YI (0.75) (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S2). The new cut-off had the highest accuracy, with a sensitivity of 85.16% and a specificity of 89.81%, and is therefore a suitable discriminator for screening of β-thalassaemia in this population. Using the currently established cut-off (HbA~2~ ≥3.5%) only yielded sensitivity and speciﬁcity values of 96.64% and 6.37%, respectively.

###### 

Number of β-globin mutations found in this study

  Mutation                                   Type        n     Number of alleles   Allele frequency (%)
  ------------------------------------------ ----------- ----- ------------------- ----------------------
  CD 17 (A\>T) (HBB:c.52A\>T)                β^0^/β^A^   166   166                 29.04
  CD 41-42 (--TCTT) (HBB:c.126_129delCTTT)   β^0^/β^A^   145   146                 26.26
  CD 26 (G\>A) (HBB:c.79G\>A)                β^+^/β^A^   107   110                 19.13
  IVS-II-654 (C\>T) (HBB:c.316-197C\>T)      β^+^/β^A^   90    92                  16.00
  --28 (A\>G) (HBB:c.-78A\>C)                β^+^/β^A^   20    20                  3.48
  CD 71/72 (+A) (HBB:c.216_217insA)          β^0^/β^A^   12    12                  2.09
  CD 27/28, +C (HBB:c.84_85insC)             β^0^/β^A^   7     7                   1.22
  IVS-I-1 (G\>T) (HBB:c.92+1G\>T)            β^+^/β^A^   5     5                   0.87
  IVS-I-5 (G\>C) (HBB:c.92+5G\>C)            β^+^/β^A^   1     1                   0.17
  CD 5 (--CT) (HBB:c.17_18delCT)             β^0^/β^A^   1     1                   0.17
  Hb Dieppe, CD 127 (A\>G) (HBB:c.383A\>G)   β^0^/β^A^   1     1                   0.17
  Initiation CD (T\>C) (HBB:c.2T\>C)         β^0^/β^A^   1     1                   0.17
  CD121 (G\>T) (HBB:c.364G\>T)               β^0^/β^A^   1     1                   0.17
  --31 (A\>C) (HBB:c.-81A\>G)                β^+^/β^A^   1     1                   0.17
  --29 (A\>G) (HBB:c.-79A\>G)                β^+^/β^A^   1     1                   0.17
  CD 43 (G\>T) (HBB:c.130G\>T)               β^0^/β^A^   1     1                   0.17
  CD 113 (T\>A) (HBB:c.341T\>A)              HbVar       1     1                   0.17
  CD 22 (A\>C) (HBB:c.68A\>C)                HbVar       1     1                   0.17
  CD 47 (G\>A) (HBB:c.142G\>A)               HbVar       1     1                   0.17
  CD 41-42/IVS-II-654                        β^0^/β^0^   1     --                  --
  IVS-II-654/CD 26                           β^0^/β^+^   1     --                  --
  CD 26/CD 26                                β^+^/β^+^   1     --                  --
  Total number of alleles                    --          566   569                 100

β^0^, production of β-globin chain is entirely eliminated; β^+^, production of β-globin chain is reduced; HBB, beta globin; Hb Dieppe, haemoglobin Dieppe; HbVar, haemoglobin variant.

###### 

Predictive value of evaluated indices of the ROC analysis for β-thalassaemia

  HbA~2~ (%)   TP        FN       FP       TN        LRP        NRP        Sn          Sp          YI
  ------------ --------- -------- -------- --------- ---------- ---------- ----------- ----------- ----------
  3.5          547       147      19       10        1.03       0.53       96.64       6.37        0.03
  3.6          540       85       26       72        1.76       0.10       95.41       45.86       0.41
  3.7          531       49       35       108       3.01       0.09       93.82       68.79       0.63
  3.8          512       35       54       122       4.06       0.12       90.46       77.71       0.68
  3.9          497       25       69       132       5.52       0.14       87.81       84.08       0.72
  **4.0**      **482**   **16**   **84**   **141**   **8.34**   **0.17**   **85.16**   **89.81**   **0.75**
  4.1          473       15       93       142       8.78       0.18       83.57       90.45       0.74
  4.2          466       13       100      144       9.94       0.19       82.33       91.72       0.74
  4.3          456       13       110      144       9.73       0.21       80.57       91.72       0.73
  4.4          449       12       117      145       10.38      0.22       79.33       92.36       0.72
  4.5          445       12       121      145       10.29      0.23       78.62       92.36       0.71

Likelihood ratio positive (LRP): sensitivity ÷ (1−specificity); likelihood ratio negative (NRP): (1−sensitivity)/specificity. Youden\'s Index (YI), sensitivity (Sn): true positive ÷ (true positive+false negative); specificity (Sp): true negative ÷ (true negative+false positive).

FN, false negative; FP, false positive; TN, true negative; TP, true positive.

Bold signifies HbA2 at the cut-off value of 4.0% yielded high values (0.898, 95% CI 0.874 to 0.919) for AUC and YI.

Haematological and electrophoretic characterisation of β-thalassaemia mutation {#s3c}
------------------------------------------------------------------------------

As shown in [tables 3](#BMJOPEN2016013367TB3){ref-type="table"} and online [supplementary](#SM2){ref-type="supplementary-material"} S2, haematological and molecular characteristics of 486 unrelated heterozygous β-thalassaemia mutations were demonstrated. The mean values for haematological and electrophoretic indices (HbA, HbA~2~, Hb, MCV and MCH) among participants with different genotypes of thalassaemia are shown in [table 3](#BMJOPEN2016013367TB3){ref-type="table"}. A signiﬁcant difference between genders was observed for Hb, with men having higher Hb compared with the women (p\<0.05), whereas no statistically significant differences were found for MCV, MCH, HbA and HbA~2~ values between the two genders ([figures 2](#BMJOPEN2016013367F2){ref-type="fig"} and [3](#BMJOPEN2016013367F3){ref-type="fig"}). The HbE group showed comparatively higher values of haematological indices (Hb, MCV and MCH) than the other four genotypes of heterozygous β-thalassaemia groups, and −28 (A\>G) (HBB (beta globin):c.−78A\>C) had signiﬁcantly higher HbA~2~ values compared with other β-thalassaemias ([table 3](#BMJOPEN2016013367TB3){ref-type="table"}).

###### 

Characterisation of eight types of β-thalassaemia and comparison (mean±SD)

  Mutation (*n*)          Hb (g/L)       MCV (fl)      MCH (pg)     HbA (%)      HbA~2~ (%)
  ----------------------- -------------- ------------- ------------ ------------ ------------
  CD 17^1^ (125)          118.26±19.14   64.78±6.98    21.52±2.67   92.08±2.24   5.91±0.54
  CD 41-42^2^ (108)       117.78±19.54   65.84±5.29    21.68±2.56   92.38±2.93   5.75±0.60
  CD 26^3^ (178)          133.04±16.67   76.99±4.52    26.06±1.55   70.67±2.28   3.87±0.44
  IVS-II-654^4^ (51)      116.57±19.11   64.81±3.93    21.17±1.06   93.06±1.62   5.55±0.45
  −28^5^ (11)             125.64±16.11   73.45±4.97    23.61±1.23   92.49±0.68   6.22±0.47
  CD 27-28^6^ (5)         106.00±18.61   68.54±2.26    22.22±0.59   88.56±5.09   5.28±0.56
  CD 71-72^7^ (5)         108.80±8.58    64.64±2.60    21.14±0.82   92.76±0.56   5.92±0.29
  IVS-I-1^8^ (3)          127.00±13.23   72.40±15.98   25.07±6.51   94.20±0.66   5.73±0.57
  Comparisons (p\<0.05)   1 vs 3         1 vs 3        1 vs 3       1 vs 3       1 vs 2
  2 vs 3                  1 vs 5         1 vs 5        1 vs 4       1 vs 3       
  3 vs 4                  2 vs 3         2 vs 3        2 vs 3       1 vs 4       
                          2 vs 5         2 vs 5        3 vs 4       2 vs 3       
                          3 vs 4         3 vs 4        3 vs 5       2 vs 4       
                          3 vs 5         3 vs 5                     2 vs 5       
                          4 vs 5         4 vs 5                     3 vs 4       
                                                                    3 vs 5       
                                                                    4 vs 5       

p Value of significant differences (p\<0.05) between various five types of β-thalassaemia is listed (n\>10). Non-listed comparisons are not significant.

Hb, haemoglobin; HbA, haemoglobin alpha; HbA2, haemoglobin alpha 2; MCV, mean cell volume; MCH, mean cell haemoglobin.

![Haematological characterisation of β-thalassaemia according to sex. \# Men have significantly higher Hb values (p\<0.05) than women. No differences were observed between genders for MCV and MCH. (n=486 total unrelated heterozygous β-thalassaemia cases). Hb, haemoglobin; MCH, mean cell haemoglobin; MCV, mean cell volume.](bmjopen2016013367f02){#BMJOPEN2016013367F2}

![Electrophoretic characterisation of β-thalassaemia according to sex in the current study. No differences were observed between genders for HbA and HbA~2~ (n=486 total unrelated heterozygous β-thalassaemia). HbA, haemoglobin alpha; HbA2, haemoglobin alpha 2.](bmjopen2016013367f03){#BMJOPEN2016013367F3}

Discussion {#s4}
==========

β-Thalassaemia is one of the most common genetic disorders worldwide, and each ethnic group has a mutation set with considerable haematological variations. Clinical features and haematological parameters in β-thalassaemia patients vary with race, lifestyle and altitude. In China, CD 17 (A\>T) (HBB:c.52A\>T), CD 41-42 (-TCTT) (HBB:c.126_129delCTTT), -28 (A\>G) (HBB:c.-78A\>C), IVS-II-654 (C\>T) (HBB:c.316-197C\>T), HbE (CD 26, G\>A) (HBB:c.79G\>A) and CD 71/72 (+A) (HBB:c.216_217insA) mutations account for more than 90% of all β-thalassaemia mutations in the Chinese population.[@R2] Characterisation and screening of these mutations provides a database to aid in the prevention and control of thalassaemia. Samples for participants used for capillary electrophoresis, cut-off value calculation and characterisation of β-thalassaemia were not collected at the same time and this is a limitation of this study. There are very few studies describing the detection and quantification of electrophoretic and haematological parameters for screening thalassaemia in the Chinese population. Thus, our report is the first characterisation of β-thalassaemia mutations in people of Southwestern China and will serve as a key reference for this population.

The majority of individuals screened in this study were women, since patients seeking prenatal diagnosis and genetic counselling represent a large portion of the study participants. Six subjects lacking an HbA band and five subjects without an HbA~2~ band were identified. Among these subjects, four were HbE homozygous, one was β-thalassaemia/HbE compound heterozygous and one had a haemoglobin variant mutation. HbA levels were significantly higher in male than female subjects in the three age groups (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1). However, no signiﬁcant difference was observed in HbA~2~ in all age groups. In our study, most of the subjects (95.45%, 14 382/15 067) had HbA~2~ levels that were within a narrow range (2.4--3.5%), similar to previous observations in Nigerian patients.[@R11]

Carriers of β-thalassaemia have increased HbA~2~ values. Of the 723 subjects analysed, the β-globin gene defect was identified in 78.28% of cases (566/723; range 1.8--7.9%). One case without the β-globin mutation had the highest HbA~2~ value (7.9%), which may be due to a haemoglobin variant coeluting with HbA~2~ peak.[@R12] Only one case of β-thalassaemia major was found in this study, which was due to the fact that children were excluded. The majority of β-thalassaemia major patients die before reaching the age of 5.[@R13]

Having an HbA~2~ level \>3.5% is the current diagnostic criterion for the β-thalassaemia trait,[@R14] while values \>4.0% are also used to identify β-thalassaemia carriers in some regions.[@R15] In this study, a higher cut-off point of HbA~2~ levels (HbA~2~ ≥4.0%) determined by ROC curves had the highest accuracy in identifying β-thalassaemia carriers. This result differed from previous reports,[@R16] which may be explained by regional differences in the spectrum and cut-off values for β-thalassaemia mutations. In our study, most β-thalassaemia mutations (497/566, 87.81%) had a mean HbA~2~ exceeding 4.0%, while silent β-thalassaemia mutations with near normal haematological indices and borderline HbA~2~ values (3.5--4.0%) were rare in our population. Therefore, the diagnostic thresholds should be increased for this population.

The cut-off point was established for all samples, including those from β-thalassaemia patients and those having abnormal haemoglobins. And Hb variant fraction could be easily screened by abnormal band for capillary electrophoresis.[@R19] In Yunnan, HbE (CD 26, G\>A) (HBB:c.79G\>A), an abnormal haemoglobin, is the most prevalent β-globin gene mutation (with a frequency of 30.5%),[@R20] with comparatively lower HbA~2~ values. Here, the mean percentage of HbA~2~ in patients with HbE was 3.87±0.44, which was similar to that reported for Americans.[@R21] HbE and other abnormal haemoglobins, such as CD 22 (A\>C) (HBB:c.68A\>C) (HbG-Coushatta), have been reported to decrease the expression of HbA~2~.[@R22] In this study, most β-thalassaemia were characterised by increased HbA~2~ values ranging from 4.3% to 6.6% (93.86%, 428/456).

Subjects with a β-globin mutation usually have lower Hb and erythrocyte indices compared with those without an identifiable mutation[@R23] and the clinical and haematological parameters in patients having β-thalassaemia are widely variable.[@R24] This study was conducted in Kunming, the capital of Yunnan province, which has an altitude of 1895 m. Regional altitude differences are a contributing factor in the variation of these parameters, as high altitudes are known to elevate Hb values. Men had higher Hb values in all five genotype groups compared with women, whereas, no statistical sex-based significant differences were observed for MCV, MCH, HbA and HbA~2~ values. These results were similar to previously reported data.[@R25] HbE (CD 26, G\>A) (HBB:c.79G\>A) is clinically asymptomatic with minimal erythrocyte morphological abnormalities in heterozygous individuals; this type had the highest MCV, MCH and Hb values in this study. Subjects with the −28 (A\>G) (HBB:c.−78A\>C) mutation (β^+^-thalassaemia), a mutation in the TATA box of the proximal promoter region, had higher MCH, MCV and HbA~2~ values compared with other β-thalassaemia types (CD 17 (A\>T) (HBB:c.52A\>T), CD 41-42 (-TCTT) (HBB:c.126_129delCTTT) and IVS-II-654 (C\>T) (HBB:c.316-197C\>T)). The −28 (A\>G) (HBB:c.−78A\>C) phenotype is similar to other β-globin gene promoter mutations.[@R26]

In conclusion, we offered a retrospective analysis of β-thalassaemia that can be used for prenatal diagnosis, genetic counselling, thalassaemia control and screening. Characterisation of β-thalassaemia and diagnostic thresholds for β-thalassaemia can be used to identify patients more precisely.
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